1337882-50-4

Basic information

• Product Name: 6-(benzyloxy)-3-bromoquinoline
• Synonyms: 6-(benzyloxy)-3-bromoquinoline;3-bromo-6-phenylmethoxyquinoline
• CAS NO: 1337882-50-4
• Molecular Formula: C₁₆H₁₂BrNO
• Molecular Weight: 314.17658
• Mol File: 1337882-50-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-(benzyloxy)-3-bromoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(benzyloxy)-3-bromoquinoline(1337882-50-4)
• EPA Substance Registry System: 6-(benzyloxy)-3-bromoquinoline(1337882-50-4)

Safety Data

• Hazardous Substances Data: 1337882-50-4(Hazardous Substances Data)

Usage

General Description

6-(Benzyloxy)-3-bromoquinoline is a chemical compound with the molecular formula C17H12BrNO, which is a derivative of quinoline. It contains a quinoline ring with a benzyloxy (C6H5CH2O-) group attached at the 6-position and a bromine atom at the 3-position. 6-(Benzyloxy)-3-bromoquinoline is used in various chemical and pharmaceutical applications, including as a building block in the synthesis of pharmaceuticals and organic compounds. It is also used as a fluorescent probe in bioimaging studies due to its unique optical properties. Additionally, 6-(Benzyloxy)-3-bromoquinoline has potential medicinal properties and may have applications in drug discovery and development. Overall, this compound has diverse uses in the fields of chemistry, pharmaceuticals, and bioimaging.

Upstream product

• 108825-21-4 6-(benzyloxy)quinoline 
• 1022151-47-8 3-bromoquinolin-6-yl acetate 
• 24306-33-0 methyl quinolin-6-ylethanoate 
• 580-16-5 6-hydroxyquinoline 
• 13669-57-3 3-bromo-6-hydroxyquinoline 
• 100-39-0 benzyl bromide 

Downstream Products

• 1393352-90-3 (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine 
• 1393352-93-6 N-((6-(benzyloxy)quinolin-3-yl)methyl)-N-ethylethanamine 
• 727650-61-5 3-aminoquinolin-6-ol 
• 1427473-83-3 1-((6-(benzyloxy)naphthalen-3-yl)methyl)-4-methylpiperazine 
• 1427473-97-9 6-(benzyloxy)-3-(4-methyl-1,4-diazepan-1-yl)quinoline 
• 1427474-50-7 6-(benzyloxy)-N-(2-(tert-butyldimethylsilyloxy)ethyl)quinolin-3-amine 
• 1427474-53-0 N-benzyl-6-(benzyloxy)quinolin-3-amine 
• 1427474-57-4 4-(6-(benzyloxy)quinolin-3-yl)-3-methylmorpholine 

Relevant articles and documents

Synthesis and antibacterial activity of novel ketolides with 11,12-quinoylalkyl side chains

A series of quinoylalkyl side chains was designed and synthesized, followed by introduction into ketolides by coupling with building block 6 or 32. The corresponding targets 7a–n, 33b, and 33e were tested for their in vitro activities against a series of macrolide-sensitive and macrolide-resistant pathogens. Some of them showed a similar antibacterial spectrum and comparable activity to telithromycin. Among them, two C2-F ketolides, compounds 33b and 33e, displayed excellent activities against macrolide-sensitive and macrolide-resistant pathogens.

6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).